CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma

od Quintás-Cardama, Alfonso
Izdano u Oncotarget (2018)

Molecular biology of bcr-abl1–positive chronic myeloid leukemia

od Quintás-Cardama, Alfonso, Cortes, Jorge
Izdano 2009

Bullet ‘Manicure’: Does Lead Prevent Hydroxyurea-induced Cutaneous Toxicity?

od Falchi, Lorenzo, Quintás-Cardama, Alfonso
Izdano u Jpn J Clin Oncol (2014)

MOLECULAR PATHWAYS: JAK/STAT PATHWAY: MUTATIONS, INHIBITORS, AND RESISTANCE

od Quintás-Cardama, Alfonso, Verstovsek, Srdan
Izdano u Clin Cancer Res (2013)

The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans

od Pant, Vinod, Quintás-Cardama, Alfonso, Lozano, Guillermina
Izdano 2012

ADVANCES AND CONTROVERSIES IN THE DIAGNOSIS, PATHOGENESIS, AND TREATMENT OF SYSTEMIC MASTOCYTOSIS

od Quintás-Cardama, Alfonso, Jain, Nitin, Verstovsek, Srdan
Izdano u Cancer (2011)

The Changing Mutational Landscape of Acute Myeloid Leukemia and Myelodysplastic Syndrome

od Larsson, Connie A., Cote, Gilbert, Quintás-Cardama, Alfonso
Izdano 2013

Investigational Immunotherapeutics for B-Cell Malignancies

od Quintás-Cardama, Alfonso, Wierda, William, O'Brien, Susan
Izdano u J Clin Oncol (2010)

Monitoring Molecular Response in Chronic Myeloid Leukemia

od Cortes, Jorge, Quintás-Cardama, Alfonso, Kantarjian, Hagop M.
Izdano u Cancer (2010)

Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia

od Quintás-Cardama, Alfonso, Han, Xin, Kantarjian, Hagop, Cortes, Jorge
Izdano 2009

Early Cytogenetic and Molecular Response During First-Line Treatment of Chronic Myeloid Leukemia in Chronic Phase: Long-Term Implications

od Quintás-Cardama, Alfonso, Cortes, Jorgé E., Kantarjian, Hagop M.
Izdano 2011

p53 pathway dysfunction in AML: beyond TP53 mutations

od Post, Sean M., Kornblau, Steven M., Quintás-Cardama, Alfonso
Izdano u Oncotarget (2017)

Prognostic Impact of the MDM2(SNP309) Allele in Leukemia and Lymphoma

od Post, Sean M., Pant, Vinod, Abbas, Hussein, Quintás-Cardama, Alfonso
Izdano 2010

Evolution of Therapies for Chronic Myelogenous Leukemia

od Santos, Fabio P S, Kantarjian, Hagop, Quintás-Cardama, Alfonso, Cortes, Jorge
Izdano 2011

THE RISE AND FALL OF GAKEKEEPER MUTATIONS? THE BCR-ABL1(T315I) PARADIGM

od Gibbons, Don L., Pricl, Sabrina, Cortes, Jorge, Quintás-Cardama, Alfonso
Izdano u Cancer (2011)

Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability

od Pant, Vinod, Xiong, Shunbin, Iwakuma, Tomoo, Quintás-Cardama, Alfonso, Lozano, Guillermina
Izdano 2011

Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia

od Quintás-Cardama, Alfonso, Kantarjian, Hagop, Pierce, Sherry, Cortes, Jorge, Verstovsek, Srdan
Izdano 2013

Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis

od Quintás-Cardama, Alfonso, Sever, Matjaz, Cortes, Jorge, Kantarjian, Hagop, Verstovsek, Srdan
Izdano u Leuk Lymphoma (2013)

SIGNIFICANCE OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH POLYCYTHEMIA VERA

od Sever, Matjaz, Quintás-Cardama, Alfonso, Pierce, Sherry, Zhou, Lingsha, Kantarjian, Hagop, Verstovsek, Srdan
Izdano 2013

PREDICTING OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AT ANY TIME DURING TYROSINE KINASE INHIBITOR THERAPY

od Quintás-Cardama, Alfonso, Choi, Sangbum, Kantarjian, Hagop, Jabbour, Elias, Huang, Xuelin, Cortes, Jorge
Izdano 2014